Recent Updates
Recently added Catalysts

SiNtx Technologies, Inc.

SINTFDA catalysts, PDUFA dates & pipeline intelligence
$1.1
▼ -0.08 · -6.78%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full SINT financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $1.0952W HIGH $4.46
Volume
38.99 K
Value Traded
43.78 K
Short % Float
2.12%
Days to Cover
7.3
-18.22%Week
-36.78%1 Month
-29.03%3 Month
-53.97%6 Month
-67.07%1 Year
-99.99%5 Year
-100%All Time

Cash Data

Unlock SINT cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
8.31 M
EPS (TTM)
-1.96
P/E Ratio
-
Ent. Value
6.36 M
Total Shares
7.56 M
Float Shares
6.06 M
Insiders
19.80%
Institutions
12.68%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every SINT catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

SINT Catalyst Timeline

Dated clinical, regulatory and corporate events for SiNtx Technologies, Inc.

Unlock the full SINT catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How SINT actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all SINT historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

SiNtx Technologies, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every SINT program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every SINT trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock SINT insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Elmore Robert RyanOfficer (President)Grant/Award 4,910 4,910 held$2.89 04/13/2026
Unlock the full SINT insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in SINT for Q3 2026.
Unlock every fund holding SINT
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in SINT
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see SINT ownership
Insider and institutional ownership, quarter by quarter.

SINT Short Interest

Shares sold short, counted twice a month.

2.12%
Short % of Float
of tradable shares sold short
128.4K
Shares Sold Short
-5.9% vs prior count
7.3 High
Days to Cover
trading days of normal volume to buy every short share back
17.6K
Avg Daily Volume
the average used for days to cover
Unlock SINT short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock SINT option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live SINT option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock SINT options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How SINT ranks across every disease it competes in

Competitive Position is a premium feature
See how SINT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

SINT News

SINT
Nov 17, 2026
SINTGeneral
▼ -9%on this news

SINTX Strengthens Patent Portfolio to Support International Growth Across Healthcare Markets

SINTX Technologies announced the issuance of two patents and three allowed applications, enhancing its intellectual property portfolio. These developments support the company's plans for international commercialization of its silicon nitride technologies across orthopedic devices, biomaterials, and medical textiles. The CEO emphasized the importance of robust IP protection for future growth.

Read more →
SINT
Nov 11, 2026
SINTGeneral

SINTX Technologies Advances SiN/PEEK 3D Printing Platform Toward Personalized Orthopedic Implant Commercialization

SINTX Technologies has completed its advanced 3D printing facility and is advancing its SiN/PEEK technology for personalized orthopedic implants. The company aims for initial product availability in 2027 and is pursuing FDA 510(k) clearance. SINTX plans to expand into craniomaxillofacial and spinal applications later in 2027, contingent on regulatory approvals.

Read more →
SINT
Nov 5, 2026
SINTGeneral

SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization

SINTX Technologies reported a significant revenue increase of over tenfold year over year for Q3 2026, alongside a 51% reduction in operating losses. The company is advancing its commercialization efforts, particularly with the launch of its SiNAPTIC® Foot & Ankle Osteotomy Wedge System. SINTX is optimistic about future growth opportunities in healthcare and other applications.

Read more →
SINT
Oct 22, 2026
SINTConferences/Events
▼ -5.7%on this news

SINTX Technologies Announces Third Quarter 2026 Earnings Release Date and Webcast

SINTX Technologies announced it will release its third quarter 2026 financial results on November 5, 2026. A conference call and webcast will follow at 4:30 p.m. ET, featuring CEO Eric Olson and CFO Kevin Trask. Interested parties can access the webcast through the company's investor relations website.

Read more →
SINT
Oct 1, 2026
SINTGeneral

SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance

SINTX Technologies reported preliminary Q3 revenue of $2.2 million, exceeding its guidance of $0.9 million to $1.1 million. This represents a 380% increase from Q2, primarily driven by industrial sales to Fortune 500 customers. The company anticipates narrower losses and continues to develop its silicon nitride technology platform.

Read more →
SINT
Sep 14, 2026
SINTConferences/Events

SINTX Technologies Announces Silicon Nitride Masterclass with Leading Orthopedics Experts

SINTX Technologies announced a Masterclass on silicon nitride in orthopedics, featuring expert discussions on its advantages over traditional materials. The event aims to educate orthopedic professionals about the material's unique properties and potential applications. SINTX is transitioning towards a medical device focus, expanding its use of silicon nitride in various orthopedic markets.

Read more →
SINT
Sep 8, 2026
SINTConferences/Events
▲ +6.7%on this news

SINTX Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference

SINTX Technologies will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. The company's executives will discuss advancements in the FDA-cleared SINAPTIC® Foot & Ankle Implant System and its proprietary silicon nitride technology. They aim to enhance commercial opportunities and support shareholder value.

Read more →
SINT
Aug 13, 2026
SINTGeneral
▲ +8.9%on this news

SINTX Technologies Regains Compliance with Nasdaq Stockholders’ Equity Requirement

SINTX Technologies has announced that it has regained compliance with Nasdaq's stockholders' equity requirement. This notification from the Listing Qualifications Staff is a positive development for the company, which specializes in advanced silicon nitride materials and medical technologies. The compliance may improve investor confidence in SINTX's financial standing.

Read more →
SINT
Aug 11, 2026
SINTGeneral
▼ -11.3%on this newsshared move

SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives

SINTX Technologies provided a mid-year business update, emphasizing its successful commercial execution and expansion of its biomaterial platform. The company outlined various strategic growth initiatives aimed at enhancing its market position. This update reflects SINTX's commitment to advancing its technology in medical and industrial applications.

Read more →
SINT
Jul 28, 2026
SINTConferences/Events

SINTX Technologies Announces Second Quarter 2026 Earnings Release Date and Webcast

SINTX Technologies announced it will release its second quarter 2026 financial results on August 11, 2026. A conference call and webcast will follow at 4:30 p.m. ET, featuring CEO Eric Olson and CFO Kevin Trask. Interested parties can access the webcast via the company's investor relations website.

Read more →
SINT
Jul 23, 2026
SINTGeneral

SINTX Technologies Engages Veteran MedTech Executive Chris Lyons and Southern Metrics to Establish Strategic Opportunity Management Program

SINTX Technologies hired Southern Metrics Consulting to manage its new Strategic Opportunity Management Program. Chris Lyons leads the firm and serves on the SINTX board. The company aims to evaluate partnerships and acquisitions to support growth. This move signals SINTX's shift toward a commercial-stage medical technology business.

Read more →
SINT
Jun 22, 2026
SINTGeneral
▼ -5.7%on this news

SINTX Technologies Announces Receipt of More Than $3.2 Million in Contract Manufacturing Purchase Orders

SINTX Technologies announced it secured over $3.2 million in purchase orders for advanced ceramic components from multiple customers. The company expects production to start in the second half of 2026 and continue into 2027. This reflects growing customer interest in SINTX's manufacturing capabilities and technical expertise.

Read more →
SINT
Jun 4, 2026
SINTGeneral

MAXIM Group Resumes Coverage on SINTX Technologies with Buy Rating and $6 Price Target

MAXIM Group has resumed coverage on SINTX Technologies, assigning a Buy rating and a price target of $6. The report emphasizes SINTX's FDA-cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System and its expanding commercialization strategy. Analysts also noted the company's proprietary manufacturing capabilities and 3D-printing initiatives as key growth drivers.

Read more →
SINT
Jun 3, 2026
SINTGeneral
▲ +7.7%on this news

SiNtx Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market

SINTX Technologies, Inc. has announced a capital raise of approximately $5.0 million, including a $4.5 million private placement priced at-the-market. The offering involves issuing 1,882,845 shares of common stock along with corresponding warrants to accredited investors. The funds are earmarked for general corporate purposes, especially in advancing the company's silicon nitride technology. The financing reflects strong investor support and is expected to enhance SINTX's strategic capabilities in the medical application sector.

Read more →
SINT
Dec 1, 2025
SINTGeneral
▼ -21.2%on this news

SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride-PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants

SINTX Technologies has signed a significant supply agreement with EVONIK to manufacture its proprietary silicon nitride-PEEK (SiN/PEEK) compound. This collaboration allows for the immediate production of AI-assisted, 3D-printed, patient-specific implants at SINTX's facility in the U.S. The agreement will enable SINTX to respond to physician requests for humanitarian-use vertebral body replacement implants, addressing critical needs in trauma and oncology. The SiN/PEEK compound is anticipated to offer advantages over standard PEEK materials.

Read more →
SINT
Nov 13, 2025
SINTFDA Updates
▼ -10.8%on this news

SINTX Reports Pivotal Third Quarter Business Update and Financial Highlights Driven by FDA Clearance, Product and IP Portfolio Expansions and Increased Operational Efficiencies

SINTX Technologies, Inc. reported a pivotal business update for the third quarter of 2025, highlighting key achievements including FDA clearance for its SINAPTIC Foot & Ankle Osteotomy Wedge System and its first commercial revenue from OsseoSculpt. The company's financial highlights show a reduction in operating expenses and improved liquidity through a recent financing activity. However, revenue has decreased compared to the previous year, raising concerns despite strong operational efficiencies and portfolio expansions. Looking ahead, SINTX plans to focus on launching the SINAPTIC wedge system and expanding clinical engagement.

Read more →
SINT
Jul 22, 2025
SINTFDA Updates
▼ -5.8%on this news

SiNtx Technologies Submits FDA 510(k) for Silicon Nitride Foot & Ankle Medical Devices Material Science Meets Surgical Precision in Groundbreaking New Platform in Reconstructive Foot & Ankle Surgery Market

SINTX Technologies has submitted a 510(k) premarket notification to the FDA for its silicon nitride osteotomy wedges, marking its entry into the reconstructive foot and ankle market. The company emphasizes the advanced biomaterial's benefits, including improved bone integration and reduced infection rates, as well as proprietary implant designs aimed at enhancing surgical efficiency. This development is projected to drive significant revenue growth, with expectations for strong early adoption by healthcare providers. However, the company acknowledges that the approval process and commercialization may encounter uncertainties.

Read more →
SINT
Jun 24, 2025
SINTGeneral

SiNtx Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market Acquisition Brings Patented Implant Designs, Seasoned Executive Team, and Near-Term Commercial Opportunities

SINTX Technologies announced the acquisition of SiNAPTIC Holdings' surgical business assets, enabling entry into the $1.3 billion foot and ankle fusion market. This acquisition includes all intellectual property and product designs related to six differentiated implant systems, aiming to accelerate commercial growth. The deal, viewed as transformative, will likely shift SINTX's focus from R&D towards revenue generation, assisted by SiNAPTIC's experienced team. However, achieving success will depend on effective commercialization and navigating regulatory hurdles.

Read more →
SINT
May 22, 2025
SINTGeneral
▼ -7.6%on this news

SiNtx Technologies Announces Patent Issuance and Formation of Subsidiary to Advance Antimicrobial Applications in the Agribiotech Market

SINTX Technologies has announced the issuance of an international patent for silicon nitride applications in agriculture, specifically for antimicrobial treatment and plant protection. The company is expanding into the agribiotech market with the formation of a subsidiary, SINTX Agribiotech, which will focus on developing sustainable agricultural technologies. Expected growth in the global antimicrobial fertilizer market highlights the potential for silicon nitride, which has shown promising results in preventing crop diseases. Nevertheless, the company acknowledges that commercialization challenges could impact future success.

Read more →
SINT
May 15, 2025
SINTGeneral

SiNtx Technologies Provides Business Update Highlighting Strategic Focus to Medical Device Commercialization Lake City, UT - May 15, 2025 - SINTX Technologies, Inc. (NASDAQ: SINT), an advanced ceramics company pioneering medical

SINTX Technologies, Inc. has announced a business update detailing its strategic shift toward medical device commercialization, focusing on silicon nitride applications. The company reported improved financials, including a cash increase and reduced operating costs. Highlighting advanced research programs and partnerships with medical OEMs, SINTX aims to meet critical healthcare needs. However, the transition carries risks related to product commercialization and market acceptance.

Read more →

About SiNtx Technologies, Inc.

Salt Lake City, UT 32 employees sintx.com
Headquarters1885 WEST 2100 STREET, SALT LAKE CITY, UT, 84119
BIOPHARMAWATCH ELITE
Trade the next SINT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime